Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

ABSTRACT:

Background

A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials.

Methods

Neutralization was assessed with tier 1 and tier 2 strains of virus in TZM-bl and A3R5 cells.

Results

Neutralization of several tier 1 viruses was detected in both RV144 and Vax003. Peak titers were higher in Vax003 and waned rapidly in both trials. The response in RV144 was targeted in

SUBMITTER: Montefiori DC 

PROVIDER: S-EPMC3392187 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature